Valuation: Proteome Sciences plc

Market Cap 6.84M 9.2M 8.04M 7.42M 12.89M 886M 13.18M 88.68M 34.88M 434M 34.55M 33.8M 1.49B P/E 2024
-2.95x
P/E 2025 -2.4x
Enterprise Value 21.83M 29.37M 25.66M 23.68M 41.14M 2.83B 42.06M 283M 111M 1.39B 110M 108M 4.77B EV / Sales 2024
4.79x
EV / Sales 2025 5.96x
Free-Float
81.91%
Yield 2024 *
-
Yield 2025 -
1 day-18.14%
Current month-18.15%
1 month-18.15%
3 months-18.15%
6 months-47.00%
Current year-47.00%
1 month 0.02
Extreme 0.02026
0.02
Current year 0.02
Extreme 0.02026
0.02
1 year 0.01
Extreme 0.0133
0.05
3 years 0.01
Extreme 0.0133
0.09
5 years 0.01
Extreme 0.0133
0.18
10 years 0.01
Extreme 0.0133
0.23
Manager TitleAgeSince
Corporate Officer/Principal - 01/04/2017
Corporate Secretary - 01/08/2017
Director TitleAgeSince
Chairman 73 30/06/2014
Director/Board Member 62 01/01/2010
Director/Board Member 71 01/07/2014
Change 5-day change 1-year change 3-year change Capi.($)
-18.14%0.00% - - 9.22M
+1.29%+6.54%-16.96%-6.48% 172B
-0.84%-1.14%-7.39%-4.38% 107B
+0.10%+1.48%+4.60%+60.26% 59.92B
-1.35%+3.78%-12.83%-38.56% 44.07B
-2.71%-2.30% - - 34.76B
-1.67%+2.08%-9.01%-44.33% 30.09B
-0.77%+2.30%+63.29%-5.68% 25.61B
-0.91%+1.31%-3.73%-18.94% 20.86B
-1.42%+0.84%-3.02%-4.62% 21.55B
Average -2.63%+3.27%+1.87%-7.84% 57.33B
Weighted average by Cap. -0.25%+3.37%-5.81%-3.42%

Financials

2024 2025
Net sales 4.89M 6.57M 5.75M 5.3M 9.21M 633M 9.42M 63.37M 24.93M 310M 24.69M 24.15M 1.07B 3.76M 5.05M 4.42M 4.07M 7.08M 487M 7.24M 48.7M 19.16M 238M 18.98M 18.56M 820M
Net income -3.41M -4.58M -4M -3.7M -6.42M -441M -6.56M -44.17M -17.37M -216M -17.21M -16.83M -744M -3.06M -4.12M -3.6M -3.32M -5.77M -397M -5.9M -39.69M -15.61M -194M -15.47M -15.13M -669M
Net Debt 13.39M 18.02M 15.75M 14.53M 25.25M 1.74B 25.81M 174M 68.31M 850M 67.67M 66.19M 2.93B 14.99M 20.17M 17.62M 16.26M 28.25M 1.94B 28.88M 194M 76.45M 951M 75.73M 74.07M 3.27B
Logo Proteome Sciences plc
Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.
Employees
32
Date Price Change Volume